An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: Despite the current treatments available for panic disorder (PD), as many as one-third of patients have persistent and treatment-resistant panic attacks. Vortioxetine is an approved medicine for major depressive disorder and has been shown to have anxiolytic properties. The purpose of this study was to evaluate its efficacy and safety in an adult population with a diagnosis of PD. Methods: The study design was open label with flexible dose strategies (5, 10, or 20 mg) with a treatment period of 10 weeks. 27 male and female subjects aged between 18 and 60 years, who met DSM-IV criteria for PD with or without agoraphobia, or who had a Panic Disorder Severity Scale (PDSS) score > 8 at baseline were enrolled. Statistical significance was established by the Student’s T test. Results: A statistically significant decrease in the occurrence of panic attacks was measured with the PDSS with vortioxetine. In addition, a moderate improvement in the quality of life and no significant side effects were observed using the Quality-of-Life Scale and Monitoring of Side Effects Scale, respectively. Conclusions: These results provide some support for the use of vortioxetine in the management of panic disorder. Trial registration ClinicalTrials.gov ID#: NCT02395510. Registered March 23, 2015,https://clinicaltrials.gov/ct2/show/NCT02395510
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multicenter Collaborative Panic Disorder Severity Scale
Shear, M. K., Brown, T. A., Barlow, D. H., Money, R., Sholomskas, D. E., Woods, S. W., Gorman, J. M., & Papp, L. A. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1571 · Cited by 1,001 · cited 1×
“The PDSS is a questionnaire developed for measuring the severity of PD and is considered a reliable tool for monitoring treatment outcome [24, 25].”
MethodKessler, R. C., Chiu, W. T., Jin, R., Ruscio, A. M., Shear, K., & Walters, E. E. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.4.415 · Cited by 795 · cited 1×
“Background Panic disorder (PD) is a common anxiety disorder affecting up to 5% of the population at a given time [1, 2].”
BackgroundEfficacy of treatments for anxiety disorders: a meta-analysis
Bandelow, B., Reitt, M., Röver, C., Michaelis, S., Görlich, Y., & Wedekind, D. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000078 · Cited by 555 · cited 1×
“In one meta-analysis of PD treatments, medications (especially serotonin–noradrenaline reuptake inhibitors) were found to be more effective based on calculated effect sizes, compared to psychotherapies and other therapies [7].”
Reliability and validity of the Panic Disorder Severity Scale: replication and extension
Shear, M. K., Rucci, P., Williams, J., Frank, E., Grochocinski, V., Vander Bilt, J., Houck, P., & Wang, T. (2001) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00028-0 · Cited by 360
Mahableshwarkar, A. R., Zajecka, J., Jacobson, W., Chen, Y., & Keefe, R. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.52 · Cited by 307
Boulenger, J.-P., Loft, H., & Olsen, C. K. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000018 · Cited by 176
Offidani, E., Guidi, J., Tomba, E., & Fava, G. A. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000353198 · Cited by 166
The Clinical Pharmacokinetics of Lu AA 21004 and its Major Metabolite in Healthy Young Volunteers
Areberg, J., Søgaard, B., & Højer, A. (2012) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2012.00886.x · Cited by 69 · cited 1×
“No statistically significant gender differences have been observed in its action [23].”
BackgroundTreatment–resistant panic disorder: a systematic review
Freire, R. C., Zugliani, M. M., Garcia, R. F., & Nardi, A. E. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1109628 · Cited by 47 · cited 1×
“Discussion Despite the current treatments available, as many as one-third of patients with PD have persistent and treatment-resistant panic attacks [28].”
BackgroundSimon, N. M., Otto, M. W., Worthington, J. J., Hoge, E. A., Thompson, E. H., LeBeau, R. T., Moshier, S. J., Zalta, A. K., & Pollack, M. H. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04485blu · Cited by 45
Cited by
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance
Melaragno, A. J. (2021) · Focus · doi:10.1176/appi.focus.20200048 · Cited by 50
Pharmacotherapy for Anxiety Disorders.
O’Leary, K. B., & Khan, J. S. (2024) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2024.04.012 · Cited by 22
Metadata
- Authors
- Shah, A., & Northcutt, J.
- Venue
- Annals of General Psychiatry
- Published
- 2018-05-11
- Volume
- 17
- Issue
- 1
- Pages
- 19-19
- ISSN
- 1744-859X (ISSN-L)
- OpenAlex
- W2806233062
- Cited by
- 23
- References
- 11
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder. https://app.cochat.ai/papers/10.1186/s12991-018-0190-6
- The paper
- Shah, A., & Northcutt, J. (2018). An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder. Annals of General Psychiatry. https://doi.org/10.1186/s12991-018-0190-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.